Floatz logo

Fludarabine

Leukemia, B-cell

Beijing Immunochina Medical Science & Technology Co., Ltd.Small moleculePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the Leukemia, B-cell cohort.

Asset / SponsorPhaseRating
Ibrutinib
Loxo Oncology, Inc.
Phase 4BBB
Cyclophosphamide
Beijing Immunochina Medical Science & Technology Co., Ltd.
Phase 2BB
Dasatinib
Nanfang Hospital, Southern Medical University
Phase 2/3B
Tucidinostat
Nanfang Hospital, Southern Medical University
Phase 2/3B
Chimeric Antigen Receptor Modified T Cells Infusion
The First Affiliated Hospital with Nanjing Medical University
Phase 2CCC

View all 16 →

Same molecule, other indications

Fludarabine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →
Fanconi anemiaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Adult Diffuse Large Cell LymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →